Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 4
1(33.3%)
3Total
N/A(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05389839Not ApplicableUnknown

Insulin Dose Calculation Software in Insulin Therapy

Role: lead

NCT05135039Not ApplicableUnknown

Intervention Effect of Canagliflozin on Prediabetes in Patients With HIV.

Role: lead

NCT01227499Completed

Differential Diagnosis of STA-PSV in Thyrotoxicosis

Role: lead

NCT02129985Phase 4Unknown

Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy

Role: lead

All 4 trials loaded